Liberty One Investment Management LLC lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 7.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 93,962 shares of the biopharmaceutical company's stock after selling 7,350 shares during the quarter. Gilead Sciences accounts for about 0.9% of Liberty One Investment Management LLC's investment portfolio, making the stock its 25th biggest holding. Liberty One Investment Management LLC's holdings in Gilead Sciences were worth $8,679,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors also recently made changes to their positions in the company. nVerses Capital LLC bought a new position in shares of Gilead Sciences during the 3rd quarter worth approximately $25,000. Valued Wealth Advisors LLC increased its position in shares of Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 161 shares during the last quarter. Decker Retirement Planning Inc. bought a new stake in Gilead Sciences during the fourth quarter worth about $29,000. Strategic Investment Solutions Inc. IL acquired a new position in Gilead Sciences during the second quarter valued at approximately $33,000. Finally, Quarry LP bought a new stake in shares of Gilead Sciences during the 2nd quarter worth approximately $43,000. Institutional investors own 83.67% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research analysts have recently commented on the stock. Barclays lifted their price objective on shares of Gilead Sciences from $84.00 to $95.00 and gave the company an "equal weight" rating in a research report on Thursday, November 7th. Morgan Stanley upgraded Gilead Sciences from an "equal weight" rating to an "overweight" rating and lifted their target price for the stock from $87.00 to $113.00 in a research note on Friday, January 10th. Wells Fargo & Company increased their price target on Gilead Sciences from $100.00 to $105.00 and gave the company an "overweight" rating in a research note on Thursday, November 7th. Leerink Partnrs raised shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Monday, October 21st. Finally, Sanford C. Bernstein began coverage on shares of Gilead Sciences in a research note on Thursday, October 17th. They set an "outperform" rating and a $105.00 target price for the company. Eleven research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $97.96.
Get Our Latest Stock Report on Gilead Sciences
Insider Activity at Gilead Sciences
In other news, CFO Andrew D. Dickinson sold 248,645 shares of Gilead Sciences stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the sale, the chief financial officer now directly owns 138,919 shares of the company's stock, valued at approximately $12,886,126.44. This trade represents a 64.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jeffrey Bluestone sold 6,788 shares of the company's stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the transaction, the director now directly owns 8,920 shares of the company's stock, valued at $815,198.80. This represents a 43.21 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 456,234 shares of company stock valued at $42,130,461 in the last quarter. Insiders own 0.29% of the company's stock.
Gilead Sciences Price Performance
GILD traded up $0.19 during trading on Friday, hitting $91.84. 6,852,085 shares of the stock traded hands, compared to its average volume of 5,370,915. The business has a 50 day moving average price of $91.75 and a 200 day moving average price of $84.08. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $98.90. The company has a market cap of $114.46 billion, a price-to-earnings ratio of 1,020.44, a PEG ratio of 1.27 and a beta of 0.18.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. During the same period in the prior year, the company earned $2.29 EPS. Gilead Sciences's revenue for the quarter was up 7.0% on a year-over-year basis. Equities research analysts forecast that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.
Gilead Sciences Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 3.35%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences's dividend payout ratio is 3,422.22%.
About Gilead Sciences
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Articles
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
